Compare Adaptive Biotechnologies Corp (ADPT) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fubotv Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.26 (market cap $3.33B), while Fubotv Inc trades at $9.71 (market cap $290.02M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11.5× Fubotv Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FUBO | |
|---|---|---|
Market Cap | $3.33B | $290.02M |
Sector | Health | Technology |
52-Week High | $22.37 | $54.72 |
52-Week Low | $10.24 | $8.09 |
Enterprise Value | $3.19B | $460.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FUBO trades at $9.85, down 3.43% today, with a neutral technical signal. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025, representing a significant turnaround to profitability. Recent developments include streaming partnerships with NBCUniversal and the BIG3 basketball league, while analyst consensus remains positive with a $16.25 price target.
FUBO presents a compelling turnaround story with improving profitability metrics and strong analyst support, though negative cash flow and high debt levels pose execution risks. The stock offers substantial upside potential if the company can maintain its path to sustainable profitability through content partnerships and advertising growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
